Explore evidence

8.8 g/dLHemoglobin (Hb) in steady state subjects was 8.8 ± 0.9.

Nigeriadrépanocytosepublished 2022The Pan African medical journalPubMeddocument of 14 observations

1.4 %The prevalence of sickle cell trait in the general population of Nigeria is 1.4%.

Nigeriadrépanocytosepublished 2022The open AIDS journaleurope_pmcdocument of 3 observations

52.2 %Forty-seven (52.2%) participants have steady state haematocrit in the range of 21-25%.

Nigeriadrépanocytosepublished 2022Annals of medicinePubMeddocument of 6 observations

100 %After 1 year, program-implementation and maintenance rates were 100%.

Nigeriadrépanocytosepublished 2022Journal of pediatric hematology/oncologyPubMeddocument of 5 observations

24.9 yearsThe mean age of the 160 female sickle cell disease patients was 24.9 years.

Nigeriadrépanocytosepublished 2021Annals of African medicinePubMeddocument of 4 observations

50 %Ischaemic ECG identified SCA children with elevated cTnT during the follow-up steady state with sensitivity 50% and specificity 39.3%.

Nigeriadrépanocytosepublished 2020Paediatrics and international child healtheurope_pmcdocument of 8 observations

300,000 individuals_per_yearApproximately 300,000 individuals are born each year with sickle cell disease in sub-Saharan Africa.

Nigeriadrépanocytosepublished 2021Frontiers in geneticseurope_pmcdocument of 3 observationsDOI 10.3389/fgene.2021.765958

54.6 %Among 209 parents of children with SCD in Ibadan, Nigeria, 54.6% reported receiving incorrect haemoglobin phenotype results.

Nigeriadrépanocytosepublished 2025BMC public healthPubMeddocument of 5 observations

15.7 %CYP2C19 *2 allele frequency was 15.7% in Nigerian patients with sickle-cell disease.

Nigeriadrépanocytose · paludismepublished 2010Journal of clinical pharmacy and therapeuticseurope_pmcdocument of 10 observations

2.4 odds_ratioBeing resident in Nigeria was independently associated with increased risk of restrictive spirometry (OR 2.4, 95% CI 1.1 to 4.9).

Nigeriadrépanocytosepublished 2019ThoraxPubMeddocument of 7 observations

Wasting, stunting, and overweight/obesity in sickle cell anemia were significantly associated with age.

Nigeriadrépanocytose · malnutrition · overweight/obesitypublished 2020Nigerian journal of clinical practicePubMeddocument of 9 observations

17 deathsSeventeen (1.4%) patients with sickle cell disease and respiratory morbidities died.

Nigeriadrépanocytose · respiratory morbiditiesobserved 2012 to 2021published 2024PloS onePubMeddocument of 12 observations

Poor metabolizers of proguanil in SCD patients are reported for the first time.

Nigeriadrépanocytosepublished 2016Pharmacology research & perspectiveseurope_pmcdocument of 5 observations

9.4 %Hydroxyurea use was less than 9.4% among the 503 SCD patients.

Nigeriadrépanocytosepublished 2025Gates open researchPubMeddocument of 5 observations

1.2 odds_ratioEach additional year of age was independently associated with increased risk of restrictive spirometry (OR 1.2, 95% CI 1.1 to 1.4).

Nigeriadrépanocytosepublished 2019ThoraxPubMeddocument of 7 observations

22 %Only 172 (22%) of the 780 mothers were aware of newborn screening for sickle cell disease.

Nigeriadrépanocytosepublished 2023West African journal of medicinePubMeddocument of 5 observations

41.1 %Thirty-nine out of 95 male patients with sickle cell disease in Ibadan, Nigeria, had experienced priapism, representing 41.1%.

Nigeriadrépanocytosepublished 2020West African journal of medicinePubMeddocument of 9 observations

9.1 %The histological pattern in the 22 patients who had renal biopsies showed interstitial nephritis in 2 (9.1%) patients.

Nigeriadrépanocytose · interstitial nephritispublished 2024The Nigerian postgraduate medical journalPubMeddocument of 10 observations

30.5 fLMean corpuscular volume (MCV) in crisis state subjects was 30.5 ± 3.1.

Nigeriadrépanocytosepublished 2022The Pan African medical journalPubMeddocument of 14 observations

3 µmMacular thickness was generally lower in SCD group in all the ETDRS map regions of the macular compared to the non-SCD group with values ranging from 3.0 to 11.5 µm.

Nigeriadrépanocytosepublished 2025The Nigerian postgraduate medical journalPubMeddocument of 6 observations

98.2 %The test efficiency of SickleSCAN™ for sickle cell disease (Hb SS and Hb SC) was 98.2%.

Nigeriadrépanocytosepublished 2017Hemoglobineurope_pmcdocument of 5 observations

1.6 yearsThe median participant follow-up was 1.6 years.

Nigeriadrépanocytosepublished 2023BloodPubMeddocument of 8 observations

25 %Recent screening-based studies suggest a β-thalassaemia trait prevalence of up to 25% among individuals without sickle cell disease (SCD) in Africa.

Nigeriadrépanocytose · β-thalassaemiapublished 2026African journal of laboratory medicineeurope_pmcdocument of 5 observations

A simplified hydroxyurea dosing strategy resulted in a substantial reduction in vaso-occlusive crises requiring emergency care in paediatric sickle cell anaemia patients in South East Nigeria.

Nigeriadrépanocytoseobserved 2022–2024published 2025BMC pediatricsPubMeddocument of 3 observations

8.9 %Sickle cell disease patients have higher hearing thresholds, with 8.9% conductive loss, 4.5% unilateral mild mixed hearing loss, and 3.3% sensorineural hearing loss.

Nigeriadrépanocytosepublished 2025Nigerian journal of clinical practicePubMeddocument of 5 observations